Lege Artis Medicinae

[Cardiovascular prevention]


MARCH 10, 2010

Lege Artis Medicinae - 2010;20(01 klsz)

[Cardiovascular diseases are the leading causes of morbidity and mortality worldwide. Before the appearance of overt symptoms of various diseases, a silent, progressive condition exists. The main goal of prevention guidelines is to reduce the incidence of first and recurrent clinical events, which include coronary heart disease, ischaemic stroke and peripheral artery disease. Modification of risk factors has been proved to reduce cardiovascular mortality and morbidity, especially in patients with a high risk. By reducing the risk of substantial cardiovascular events it is possible to ameliorate premature disability, prolong survival and improve quality of life. We would like to emphasize the importance of lifestyle changes, the management of major cardiovascular risk factors and the use of various prophylactic drug therapies in the prevention of cardiovascular diseases. Medical intervention strategies for high-risk patients include the use of acetilsalycilic acid, statin, beta-blocker, ACE-inhibitor and anticoagulant for the treatment of any disease where the use of such drugs has been supported by evidence. The specific preventive effect of a drug is considered to be verified if the drug significantly reduced the incidence of pirmary vascular outcomes, beyond its primary pharmacodynamic effect, or if it is likely to have such an effect according to adequately powered metaanalyses.]



Further articles in this publication

Lege Artis Medicinae

[HOPE: Heart Outcomes Prevention Evaluation]


All articles in the issue

Related contents

LAM Extra for General Practicioners

[Similarities and differences in the renal effects of statins]


[By efficiently reducing serum cholesterol level, statins significantly decrease both cardiovascular morbidity and mortality. Decreasing LDL-cholesterol level by 1% reduces coronary mortality risk by 1%, whereas increasing HDL-cholesterol level by 1% reduces the risk by 3%. At the same time, renal failure significantly increases cardiovascular events and/or mortality compared with the population mean. It is an exciting question whether statins are able to prevent and decelerate the deterioration of kidney function deterioration, preserve GFR and decrease albuminuria. Depending on the strength of their effect, statins have different cholesterol-lowering capacity (rosuvastatin and atorvastatin are especially effective). An important question is whether these differences can be detected in the renal function as well. The results of experimental data and major clinical trials (e.g. AURORA, PLANET I-II, SHARP) are often controversial. Nevertheless, statin therapy has advantages for patients with kidney diseases, although to a lesser extent than it has in the normal population.]

Lege Artis Medicinae


NAGY László

[Controlled clinical studies on statins have produced evidence that the aggressive lowering of LDL-cholesterol (LDL-C) level reduces the mortality rate of ischaemic heart disease. About 40% of treated patients achieve the cholesterol target level. The observance of medication instructions on a daily basis (compliance) and willingness for long-term taking of the drug (persistence) are crucially important to avoid severe complications. In the long term, patients take only about 50% of their medicines according to the instructions. As a result of the generally poor compliance and persistence in taking the medications, the decrease in morbidity and mortality observed in clinical studies do not occur under real-life conditions. Patients with poor compliance (<80%) will experience only a minimal health benefit and the cost-effectiveness of the therapy will markedly decrease. For patients with poor persistence who discontinue their treatment before benefits at the clinical endpoints could manifest, the resources invested into the therapy will be lost. Both compliance and persistence deteriorate as the number of concurrently taken medicines increases. Since less than 50% of the programmes aimed at improving patient co-operation are successful, therapeutic decisions should preferably be made by taking into consideration the expected compliance/persistence already at the time of choosing the medication. By widening the use of fixed-dose combination therapies, the efficiency of treatment can substantially be increased in patients who concurrently take several medicines and require aggressive lowering of blood pressure or LDL-C level.]

Lege Artis Medicinae

[The atherosclerosis can not only be prevented, but also can be cured ]

MÁRK László

[The process of atherosclerosis nowadays plays an important role in the health care not just as a major cause of the most common cardiovascular diseases which lead to death, but also as a major factor in the loss of age-related elasticity in the blood vessels. Over the past two decades, large studies have shown that the treatment of high cholesterol levels can reduce the frequency of cardiovascular events and death and have confirmed the ability to reduce the already existing atherosclerotic plaque, which is almost unique in pharmacotherapy. Using lipid lowering therapy, if we do it properly, we can not only prevent vascular events, but can also cure atherosclerosis. Currently there are three drug groups (statins, ezetimibe and PCSK9- inhibitors), which have complete evidence that their use can reduce the number of cardiovascular events and plaque regression can be achieved. Despite many convincing clinical trials, lipid-lowering therapy is on the cardiovascular prevention palette in the just tolerated or forced applied category. In order to take advantage of its potentials at an appropriate level, as doctors, we have to approach to it by considering its importance. We should communicate to our patients that it’s about a life-long treatment, which not only can reduce the possibility of cardiovascular events, but also can slow down the aging process of the arteries. ]

Hypertension and nephrology

[ACEi or ARB? What are the results of the comparative analysis?]


[Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are treatment options for patients with cardiovascular disease (CVD) or those with cardiovascular risk factors. The comparative efficacy and safety of ACEis and ARBs have been much debated. To compare the benefits of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure a metaanalysis was carried out based on 254.301 subjects of 106 randomised trials. Meta-analysis included randomized trials of ACEis and ARBs compared with placebo or active controls and corroborated with head-to-head trials of ARBs vs ACEis. According to placebo controlled studies ACEis but not ARBs reduced all-cause mortality, cardiovascular mortality and MI. It seems that ACEis are more effective than ARBs. But this is only true if we take into account the trials before 2000. The analysis restricted to trials published after 2000 revealed similar outcomes with ACEis vs placebo and ARBs vs placebo. Head-to-head comparison trials of ARBs vs ACEis exhibited no difference in outcomes. The underlying causes and details are explained in this review.]

Hypertension and nephrology

[Gender differences in blood pressure values throughout the life course]